Neurobiology

Faculty of Medicine | Lund University

Menu

Neurobiology: Björklund Group

 

anders bjo rklund

Anders Björklund, Professor, Head of the Neurobiology Unit


Development of restorative and neuroprotective treatment strategies for Parkinson´s disease

Our research aims at developing new restorative and neuroprotective treatments for neurodegenerative diseases using cell transplantation and direct in vivo gene delivery.

The Neurobiology Unit seeks to develop techniques for isolation and identification of neural progenitor cells with the capacity to generate fully functional dopamine neurons after transplantation to the Parkinsonian brain. We use cell sorting and cell engineering techniques to generate dopamine neuron precursor cells specifically for transplantation purposes, and explore techniques for insertion of genes into stem cells to direct the development of stem cells into transplantable midbrain dopamine neurons.

In a second line of research we explore rodent models of Parkinson´s disease to study the mechanisms underlying development of L-DOPA-induced dyskinesias, and use recombinant viral vectors as tools to model Parkinson-like neurodegeneration in rodents, and for delivery of putative therapeutic factors, GDNF and Nurr 1 in particular, to the brain.


News

2016-09-21. På svenska: Läs här om Parkinson Förbundets besök på BMC (Biomedicinskt Centrum) den 7 september 2016:


2016-05-12. New publication available
Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain.


2015-06-03.  On new therapeutic principle for Parkinsonian dyskinesia.
To learn more about the results of a new treatment study which Anders Björklund's lab participated in, please see the following Lund University Neuroscience Newsletter, 1/2015:


2015-02-11. På svenska: Ny publikation
Här kan du läsa om en ny behandlingsprincip mot ofrivilliga rörelser vid Parkinsons och vår senaste publikation "Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study".


Site overview